Jyong Biotech Ltd (MENS)

Jul 26, 2025

Jyong Biotech's Plant‑Based Pipeline Targets Huge Markets But Risks Remain - Seeking Alpha

Jul 26, 2025

Jul 25, 2025

Jyong Biotech Ltd.'s Quiet Period Will End on July 28th (NASDAQ:MENS) - MarketBeat

Jul 25, 2025

Jul 22, 2025

Jyong Biotech Ltd. Completes Nasdaq IPO and Showcases MCS®-2 at BIO 2025 International Convention - Nasdaq

Jul 22, 2025

Jul 22, 2025

Jyong Biotech Completes Nasdaq IPO, Participates in BIO 2025 Convention. - AInvest

Jul 22, 2025

Jul 22, 2025

Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention - GlobeNewswire

Jul 22, 2025

Jul 22, 2025

Taiwan's Jyong Biotech Takes On $9.8B BPH Market With Revolutionary Plant-Based Treatment After Nasdaq IPO - Stock Titan

Jul 22, 2025

Jul 21, 2025

Jyong Biotech Ltd.’s Quiet Period Set To Expire on July 28th (NASDAQ:MENS) - Defense World

Jul 21, 2025

Jul 08, 2025

Biopharma financings total $28.7B in H1, down 59% from 2024 - BioWorld MedTech

Jul 08, 2025

Jul 03, 2025

Jyong Biotech shares fall 3.33% in premarket after Wall Street Zen upgrades rating to 'hold'. - AInvest

Jul 03, 2025

Jul 02, 2025

Yong Biotech Ltd (Nasdaq:MENS) Marks Milestone at Nasdaq Composite MarketSite - Kalkine Media

Jul 02, 2025

Jul 02, 2025

Jyong Biotech shares fall 3.12% in after-hours after Wall Street Zen upgrades rating to 'hold' and CEO rings closing bell at Nasdaq. - AInvest

Jul 02, 2025

Jul 01, 2025

Pre-market Movers: BGLC, ATAI, GOVX, SNGX... - RTTNews

Jul 01, 2025

Jun 30, 2025

Jyong Biotech shares fall 4.92% in after-hours following a 34.80% surge post-Nasdaq listing and 11.04% gain over the past five days. - AInvest

Jun 30, 2025

Jun 27, 2025

Jyong Biotech shares rise 2.11% intraday as biotech sector gains and company completes $20M IPO. - AInvest

Jun 27, 2025

Jun 26, 2025

Jyong Biotech shares rise 11.82% intraday after successful $20 million IPO and addition to Nasdaq Composite Index. - AInvest

Jun 26, 2025

Jun 24, 2025

Jyong’s $20M US IPO to help refile NDA of urological botanic drug - BioWorld MedTech

Jun 24, 2025

Jun 20, 2025

Jyong Biotech Soars 11.13% Post $20M IPO - AInvest

Jun 20, 2025

Jun 19, 2025

MENSJyong Biotech Ltd. Latest Stock News & Market Updates - Stock Titan

Jun 19, 2025

Jun 18, 2025

Jyong Biotech Plunges 10.98% Despite IPO Surge - AInvest

Jun 18, 2025

Jun 17, 2025

Jyong Biotech Ltd. IPO opens at $15 after pricing at $7.50 per share - Investing.com Nigeria

Jun 17, 2025

Jun 16, 2025

Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering - GlobeNewswire

Jun 16, 2025

Feb 10, 2025

Jyong Biotech Seeks US IPO On Thin Capitalization And Uphill Regulatory Battle (MENS) - Seeking Alpha

Feb 10, 2025

Feb 06, 2025

MENS IPO NewsUrinary disease biotech Jyong Biotech sets terms for $19 million US IPO - renaissancecapital.com

Feb 06, 2025

Mar 07, 2024

Commercial-ready Taiwanese biotech developing therapies for urinary diseases. - renaissancecapital.com

Mar 07, 2024

Dec 20, 2023

JYB IPO NewsUrinary disease biotech Jyong Biotech withdraws $40 million US IPO - renaissancecapital.com

Dec 20, 2023

Aug 18, 2023

Jyong Biotech Ltd. Begins U.S. IPO Rollout (Pending:JYB) - Seeking Alpha

Aug 18, 2023

Nov 30, 2022

Laxton Investments Company Ltd. v. Jyong Biotech Ltd. et al: Originating Summons - OffshoreAlert

Nov 30, 2022